Transdermal Estrogen for the Treatment of Bone Loss in Women With Anorexia Nervosa
Pouneh K. Fazeli, MD
Summary
Randomized, placebo-controlled study investigating the use of physiologic, transdermal estrogen for low bone mass in adult women with anorexia nervosa.
Description
Anorexia nervosa is a prevalent psychiatric with a lifetime prevalence of up to 2.2%. Among the many medical co-morbidities associated with anorexia nervosa, the most common is significant bone loss, which can persist despite weight recovery. Nearly 90% of women with anorexia nervosa have osteopenia and this low bone mass is associated with an increased fracture risk. Nearly 30% of women with anorexia nervosa report a history of a fracture and a prospective study demonstrated a 7-fold increased risk of fracture in women with anorexia nervosa compared to age-matched controls. Because anorexia n…
Eligibility
- Age range
- 19–45 years
- Sex
- Female
- Healthy volunteers
- No
Inclusion Criteria: 1. Female 2. 19-45 years of age 3. DSM-5 psychiatric criteria for anorexia nervosa 4. \<85% of ideal body weight as defined by the 1983 Metropolitan Life Insurance Height and Weight Tables 5. Amenorrhea 6. T-score of \< -1.0 at spine or hip Exclusion Criteria: 1. Diseases known to affect bone metabolism, including untreated thyroid dysfunction, vitamin D deficiency, Cushing's syndrome, diabetes mellitus or renal insufficiency (eGFR \< 60) 2. Personal history of venous or arterial clot 3. History of stroke or myocardial infarction 4. History of hypercoagulable disorder 5.…
Interventions
- DrugTransdermal estrogen
Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) weekly patch
- DrugPlacebos
Placebo weekly patch
Location
- University of Pittsburgh School of MedicinePittsburgh, Pennsylvania